Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN04 + Chemotherapy in Advanced Solid Tumors (CESTAFOUR)
NCT05116891Phase 2Completed
- Sponsor
- Cantargia AB
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nadunolimab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), solid tumor (advanced stage), sponsored by Cantargia AB. Started Sep 2021; status: completed.
02
Drugs
nadunolimab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)biliary tract cancer (BTC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05116891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116891.